Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab monotherapy.Methods Eligible pat...

Full description

Bibliographic Details
Main Authors: Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/3/e004780.full

Internet

https://jitc.bmj.com/content/11/3/e004780.full

Similar Items